- Home
- / Greenwich LifeSciences
Greenwich LifeSciences
Stock Price
$14.1
2024-10-29
Market Capitalization
$186 M
2024-10-29
Greenwich LifeSciences Summary
Company Summary
- Overview
- Greenwich LifeSciences is a clinical-stage biopharmaceutical company. It develops peptide immunotherapy for breast cancer.
- Type
- Public
- Status
- Active
- Founded
- 2006
- HQ
- Stafford, TX, US | view all locations
- Cybersecurity rating
Table of Contents
Key People
F. Joseph Daugherty, Chief Medical Officer, Director
Jaye Thompson, VP Clinical & Regulatory Affairs
David B. McWilliams, Chairman of the Board
LocationsView all
1 location detected
Stafford, TX HQ
United States
3992 Bluebonnet Dr building 14
Greenwich LifeSciences Financials
Summary Financials
- Net income (Q3, 2025)
- ($4.2M)
- Cash (Q3, 2025)
- $3.8M
- EBIT (Q3, 2025)
- ($4.2M)